Author/Authors :
Naddafi, Fatemeh Pharmaceutical Sciences Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Davami, Fatemeh Biotechnology Research Center - Pasteur Institute of Iran, Tehran, Iran , Tabarzad, Maryam Protein Technology Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Barkhordari, Farzaneh Biotechnology Research Center - Pasteur Institute of Iran, Tehran, Iran , Shirazi, Farshad H Pharmaceutical Sciences Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Blinatumomab, the bispecific T cell engager antibody (BsAb), has been demonstrated
as the most successful BsAb to date. Throughout the past decade, vector design has great
importance for the expression of monoclonal antibody in Chinese hamster ovary (CHO) cells.
It has been indicated that expression vectors based on the elongation factor-1 alpha (EF-1
alpha) gene and DHFR selection marker can be highly effective to produce populations of
stably transfected cells in the selection medium. Moreover, the phiC31 integrase system is
considered as an attractive and safe protein expression system in mammalian cells and it could
integrate a donor plasmid of any size, as a single copy, in to the host genome with no cofactors.
In this study, phiC31 integrase technology in combination with DHFR amplification system
was used to have an expression vector for future expression of blinatumomab in CHO cells.
The gene of interest (BsAb gene) could be joined to DHFR selection marker with the insertion
of an internal ribosome entry site (IRES). By positioning the DHFR downstream of BsAb gene
and IRES, the transcription of the selection marker can depend on the successful transcription
of the BsAb gene, which was located upstream in the expression construct. In this study,
FC550A-1 vector was used as the backbone and DHFR selection marker was successfully
combined with phiC31 integrase technology to generate a high-expressing construct for BsAb
expression in CHO-DG44 cells in future studies.
Keywords :
CHO cells , DHFR , phiC31 integrase , Blinatumomab , FC550A-1 vector